NCT00958516

Assessment of the Phototoxic Potential of LEO 29102 Cream

A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this trial is to evaluate the phototoxic potential of a single application on healthy skin of LEO 29102 cream in different doses.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LEO 29102 cream	LEO 29102 cream in different doses and the cream vehicle

Timeline

• Start date: 2009-09-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2009-08-13
• Last updated: 2025-02-24

Locations

1 site across 1 country: France